✦ LIBER ✦

Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme

✍ Scribed by Chris J. Tyrrell; Heather Payne; William A. See; David G. McLeod; Manfred P. Wirth; Peter Iversen; Jon Armstrong; Clive Morris; on behalf of the ‘Casodex’ Early Prostate Cancer Trialists' Group

Book ID: 118496494
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 245 KB
Volume: 76
Category: Article
ISSN: 0167-8140
DOI: 10.1016/j.radonc.2005.06.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bicalutamide (‘casodex’) 150 mg as adjuv

Bicalutamide (‘casodex’) 150 mg as adjuvant to radiotherapy in localised or locally advanced prostate cancer

✍ C. Tyrrell; H. Payne; M. Wirth; P. Iversen; W. See; D. McLeod; B.-E. Persson; K. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 186 KB

Bicalutamide (“Casodex”) 150 mg as adjuv

Bicalutamide (“Casodex”) 150 mg as adjuvant to radiotherapy in localized or locally advanced prostate cancer

✍ C. Tyrrell; H. Payne; W. See; D. McLeod; M. Wirth; P. Iversen; R. Beckman; K. Ca 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 44 KB

182 Bicalutamide (‘Casodex’) 150 mg as a

182 Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy significantly improves progression-free survival in early non-metastatic prostate cancer: Results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow-up

✍ D. McLeod; P. Iversen; W. See; M. Wirth; K. Carroll; C. Morris; T. Morris 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 237 KB

Bicalutamide (Casodex) 150 mg as immedia

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

✍ M Wirth; C Tyrrell; M Wallace; K.P Delaere; M Sánchez-Chapado; J Ramon; J Hether 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 223 KB

Antiandrogen monotherapy in patients wit

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

✍ Peter Iversen; David G. McLeod; William A. See; Thomas Morris; Jon Armstrong; Ma 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 404 KB

Antiandrogen monotherapy in patients wit

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7years

✍ Kibel, A.S. 📂 Article 📅 2011 🏛 Elsevier Science ⚖ 46 KB

Bicalutamide (‘Casodex’) 150&#xa0;mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme

Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme